Cargando…
Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy
Antiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation prese...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068321/ https://www.ncbi.nlm.nih.gov/pubmed/35528114 http://dx.doi.org/10.1155/2022/5340953 |
_version_ | 1784700200937324544 |
---|---|
author | Archer, Mary-Ann Kumadoh, Doris Gaizer, Samuel Nii-Bortier Mensah, Adelaide Jato, Jonathan Kyene, Micheal Odoi Mintah, Susana Oteng Yeboah, Genevieve Naana Sodzi, Paul kwesi Adi-Dako, Ofosua |
author_facet | Archer, Mary-Ann Kumadoh, Doris Gaizer, Samuel Nii-Bortier Mensah, Adelaide Jato, Jonathan Kyene, Micheal Odoi Mintah, Susana Oteng Yeboah, Genevieve Naana Sodzi, Paul kwesi Adi-Dako, Ofosua |
author_sort | Archer, Mary-Ann |
collection | PubMed |
description | Antiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation presents notable challenges in patients' adherence to treatment regimen due to its bulkiness and bitterness. These challenges have resulted in a decrease in therapeutic outcome. This study sought to transform Antiaris into oral capsules to mask its bitter taste and reduce bulkiness of the product to improve patients' convenience. In this study, four (4) conventional release capsule formulations were successfully prepared from the decoction via wet granulation using corn starch, lactose, light magnesium carbonate (LMC), and microcrystalline cellulose (MCC) and labelled A01, A02, A03, and A04 respectively. The drug-excipient compatibility studies on A01, A02, A03, and A04 were investigated using Fourier transform infrared (FTIR) spectroscopy. The flow properties of the granules as well as the quality assessment of the formulations such as dissolution, disintegration, uniformity of weight, and assay tests were evaluated using pharmacopoeial and nonpharmacopoeial methods. Appropriate models were used to investigate the difference factor (f(1)) and similarity factor (f(2)) of the dissolution profiles of the formulations and Antiaris. From the study, all formulated granules had excellent flow properties with Carr's index from 7.83 to 9.56%, Hausner's ratio from 1.09 to 1.10, and angle of repose from 25.13 to 27.87°. Drug-excipient compatibility studies demonstrated no interaction between extract and used excipients. All formulations passed the uniformity of weight, disintegration, assay, and dissolution tests. Formulation A02 had the highest dissolution efficiency of 100.12%, while A03 recorded the least value of 97.22% in the 1 h dissolution studies. A comparison of their various dissolution profiles, respectively, to that of its decoction demonstrated their similarity, since, in all comparisons, f(2) < 15 and f(1) > 50. This implies that, any of these four formulations could be a good substitute for Antiaris. |
format | Online Article Text |
id | pubmed-9068321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-90683212022-05-05 Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy Archer, Mary-Ann Kumadoh, Doris Gaizer, Samuel Nii-Bortier Mensah, Adelaide Jato, Jonathan Kyene, Micheal Odoi Mintah, Susana Oteng Yeboah, Genevieve Naana Sodzi, Paul kwesi Adi-Dako, Ofosua Adv Pharmacol Pharm Sci Research Article Antiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation presents notable challenges in patients' adherence to treatment regimen due to its bulkiness and bitterness. These challenges have resulted in a decrease in therapeutic outcome. This study sought to transform Antiaris into oral capsules to mask its bitter taste and reduce bulkiness of the product to improve patients' convenience. In this study, four (4) conventional release capsule formulations were successfully prepared from the decoction via wet granulation using corn starch, lactose, light magnesium carbonate (LMC), and microcrystalline cellulose (MCC) and labelled A01, A02, A03, and A04 respectively. The drug-excipient compatibility studies on A01, A02, A03, and A04 were investigated using Fourier transform infrared (FTIR) spectroscopy. The flow properties of the granules as well as the quality assessment of the formulations such as dissolution, disintegration, uniformity of weight, and assay tests were evaluated using pharmacopoeial and nonpharmacopoeial methods. Appropriate models were used to investigate the difference factor (f(1)) and similarity factor (f(2)) of the dissolution profiles of the formulations and Antiaris. From the study, all formulated granules had excellent flow properties with Carr's index from 7.83 to 9.56%, Hausner's ratio from 1.09 to 1.10, and angle of repose from 25.13 to 27.87°. Drug-excipient compatibility studies demonstrated no interaction between extract and used excipients. All formulations passed the uniformity of weight, disintegration, assay, and dissolution tests. Formulation A02 had the highest dissolution efficiency of 100.12%, while A03 recorded the least value of 97.22% in the 1 h dissolution studies. A comparison of their various dissolution profiles, respectively, to that of its decoction demonstrated their similarity, since, in all comparisons, f(2) < 15 and f(1) > 50. This implies that, any of these four formulations could be a good substitute for Antiaris. Hindawi 2022-04-27 /pmc/articles/PMC9068321/ /pubmed/35528114 http://dx.doi.org/10.1155/2022/5340953 Text en Copyright © 2022 Mary-Ann Archer et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Archer, Mary-Ann Kumadoh, Doris Gaizer, Samuel Nii-Bortier Mensah, Adelaide Jato, Jonathan Kyene, Micheal Odoi Mintah, Susana Oteng Yeboah, Genevieve Naana Sodzi, Paul kwesi Adi-Dako, Ofosua Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
title | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
title_full | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
title_fullStr | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
title_full_unstemmed | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
title_short | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
title_sort | development and in vitro evaluation of oral capsules from antiaris: a convenient substitute for peripheral neuropathy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068321/ https://www.ncbi.nlm.nih.gov/pubmed/35528114 http://dx.doi.org/10.1155/2022/5340953 |
work_keys_str_mv | AT archermaryann developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT kumadohdoris developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT gaizersamuelniibortier developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT mensahadelaide developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT jatojonathan developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT kyenemichealodoi developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT mintahsusanaoteng developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT yeboahgenevievenaana developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT sodzipaulkwesi developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT adidakoofosua developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy |